358 related articles for article (PubMed ID: 33431814)
1. Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma.
Nguyen PHD; Ma S; Phua CZJ; Kaya NA; Lai HLH; Lim CJ; Lim JQ; Wasser M; Lai L; Tam WL; Lim TKH; Wan WK; Loh T; Leow WQ; Pang YH; Chan CY; Lee SY; Cheow PC; Toh HC; Ginhoux F; Iyer S; Kow AWC; Young Dan Y; Chung A; Bonney GK; Goh BKP; Albani S; Chow PKH; Zhai W; Chew V
Nat Commun; 2021 Jan; 12(1):227. PubMed ID: 33431814
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma.
Dong LQ; Peng LH; Ma LJ; Liu DB; Zhang S; Luo SZ; Rao JH; Zhu HW; Yang SX; Xi SJ; Chen M; Xie FF; Li FQ; Li WH; Ye C; Lin LY; Wang YJ; Wang XY; Gao DM; Zhou H; Yang HM; Wang J; Zhu SD; Wang XD; Cao Y; Zhou J; Fan J; Wu K; Gao Q
J Hepatol; 2020 May; 72(5):896-908. PubMed ID: 31887370
[TBL] [Abstract][Full Text] [Related]
3. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma.
Chew V; Chen J; Lee D; Loh E; Lee J; Lim KH; Weber A; Slankamenac K; Poon RT; Yang H; Ooi LL; Toh HC; Heikenwalder M; Ng IO; Nardin A; Abastado JP
Gut; 2012 Mar; 61(3):427-38. PubMed ID: 21930732
[TBL] [Abstract][Full Text] [Related]
4. Multi-region sequencing with spatial information enables accurate heterogeneity estimation and risk stratification in liver cancer.
Yang C; Zhang S; Cheng Z; Liu Z; Zhang L; Jiang K; Geng H; Qian R; Wang J; Huang X; Chen M; Li Z; Qin W; Xia Q; Kang X; Wang C; Hang H
Genome Med; 2022 Dec; 14(1):142. PubMed ID: 36527145
[TBL] [Abstract][Full Text] [Related]
5. A transcriptomic intratumour heterogeneity-free signature overcomes sampling bias in prognostic risk classification for hepatocellular carcinoma.
Luo S; Jia Y; Zhang Y; Zhang X
JHEP Rep; 2023 Jun; 5(6):100754. PubMed ID: 37234275
[TBL] [Abstract][Full Text] [Related]
6. Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma.
Xu LX; He MH; Dai ZH; Yu J; Wang JG; Li XC; Jiang BB; Ke ZF; Su TH; Peng ZW; Guo Y; Chen ZB; Chen SL; Peng S; Kuang M
Ann Oncol; 2019 Jun; 30(6):990-997. PubMed ID: 30916311
[TBL] [Abstract][Full Text] [Related]
7. Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma.
Shen YC; Hsu CL; Jeng YM; Ho MC; Ho CM; Yeh CP; Yeh CY; Hsu MC; Hu RH; Cheng AL
J Hepatol; 2020 Mar; 72(3):489-497. PubMed ID: 31634533
[TBL] [Abstract][Full Text] [Related]
8. A signature of 33 immune-related gene pairs predicts clinical outcome in hepatocellular carcinoma.
Sun XY; Yu SZ; Zhang HP; Li J; Guo WZ; Zhang SJ
Cancer Med; 2020 Apr; 9(8):2868-2878. PubMed ID: 32068352
[TBL] [Abstract][Full Text] [Related]
9. A novel hypoxia gene signature indicates prognosis and immune microenvironments characters in patients with hepatocellular carcinoma.
Zhang Q; Qiao L; Liao J; Liu Q; Liu P; Liu L
J Cell Mol Med; 2021 Apr; 25(8):3772-3784. PubMed ID: 33616276
[TBL] [Abstract][Full Text] [Related]
10. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses.
Chew V; Lai L; Pan L; Lim CJ; Li J; Ong R; Chua C; Leong JY; Lim KH; Toh HC; Lee SY; Chan CY; Goh BKP; Chung A; Chow PKH; Albani S
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5900-E5909. PubMed ID: 28674001
[TBL] [Abstract][Full Text] [Related]
11. Annexin A2 promotion of hepatocellular carcinoma tumorigenesis
Qiu LW; Liu YF; Cao XQ; Wang Y; Cui XH; Ye X; Huang SW; Xie HJ; Zhang HJ
World J Gastroenterol; 2020 May; 26(18):2126-2137. PubMed ID: 32476780
[TBL] [Abstract][Full Text] [Related]
12. Transcriptomic analysis of a transgenic zebrafish hepatocellular carcinoma model reveals a prominent role of immune responses in tumour progression and regression.
Li Z; Luo H; Li C; Huo X; Yan C; Huang X; Al-Haddawi M; Mathavan S; Gong Z
Int J Cancer; 2014 Oct; 135(7):1564-73. PubMed ID: 24550086
[TBL] [Abstract][Full Text] [Related]
13. PKM2 Drives Hepatocellular Carcinoma Progression by Inducing Immunosuppressive Microenvironment.
Li TE; Wang S; Shen XT; Zhang Z; Chen M; Wang H; Zhu Y; Xu D; Hu BY; Wei R; Zheng Y; Dong QZ; Qin LX
Front Immunol; 2020; 11():589997. PubMed ID: 33193421
[TBL] [Abstract][Full Text] [Related]
14. Metabolic reprogramming of immune cells: Shaping the tumor microenvironment in hepatocellular carcinoma.
Xia Y; Brown ZJ; Huang H; Tsung A
Cancer Med; 2021 Sep; 10(18):6374-6383. PubMed ID: 34390203
[TBL] [Abstract][Full Text] [Related]
15. Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications.
Cariani E; Missale G
Liver Int; 2019 Sep; 39(9):1608-1621. PubMed ID: 31314948
[TBL] [Abstract][Full Text] [Related]
16. Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer.
Schneider C; Teufel A; Yevsa T; Staib F; Hohmeyer A; Walenda G; Zimmermann HW; Vucur M; Huss S; Gassler N; Wasmuth HE; Lira SA; Zender L; Luedde T; Trautwein C; Tacke F
Gut; 2012 Dec; 61(12):1733-43. PubMed ID: 22267597
[TBL] [Abstract][Full Text] [Related]
17. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
18. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification.
Kurebayashi Y; Ojima H; Tsujikawa H; Kubota N; Maehara J; Abe Y; Kitago M; Shinoda M; Kitagawa Y; Sakamoto M
Hepatology; 2018 Sep; 68(3):1025-1041. PubMed ID: 29603348
[TBL] [Abstract][Full Text] [Related]
19. Genetic and non-genetic clonal diversity in cancer evolution.
Black JRM; McGranahan N
Nat Rev Cancer; 2021 Jun; 21(6):379-392. PubMed ID: 33727690
[TBL] [Abstract][Full Text] [Related]
20. Identification of immunological subtypes of hepatocellular carcinoma with expression profiling of immune-modulating genes.
Cao D; Chen MK; Zhang QF; Zhou YF; Zhang MY; Mai SJ; Zhang YJ; Chen MS; Li XX; Wang HY
Aging (Albany NY); 2020 Jun; 12(12):12187-12205. PubMed ID: 32544882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
